SUV Max as Predictor of Outcome in Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01262144
Recruitment Status : Completed
First Posted : December 17, 2010
Last Update Posted : December 17, 2010
Information provided by:
Rambam Health Care Campus

Brief Summary:

Cervical Cancer is staged clinically, not surgically. Patients in whom an extensive disease is identified are not usually eligible for surgery. PET-CT is used to support staging. However, some patients received surgery after staging and subsequently require radio/chemotherapy due to findings on operation.

This study will attempt to find a correlation between SUV-Max on PET-CT and subsequent outcomes i.e. need for adjuvant therapy.

Condition or disease Intervention/treatment
Cervical Cancer Radiation: Radiotherapy

Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: A Study to Evaluate the Value of SUV-Max in PET-FDG in Predicting Outcome of Surgery Vis a Vis Need for Radiotherapy
Study Start Date : August 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer
U.S. FDA Resources

Group/Cohort Intervention/treatment
Case group Radiation: Radiotherapy
Radiotherapy for cervical cancer

Primary Outcome Measures :
  1. Administration of adjuvant therapy [ Time Frame: immediately following surgery ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: surgery - present day ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Females age 18-80, diagnosed with cervical cancer

Inclusion Criteria:

  • having stating PET-CT stored on site
  • treated with surgery

Exclusion Criteria:

  • not eligible for surgery based on PET-CT, clinical stage

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01262144

Rambam Medical Center
City, Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
Principal Investigator: Amnon Amit, MD Rambam Health Care Campus

Responsible Party: Dr. Amit Amnon, director, gynecologic oncology unit, Rambam Health Care Campus Identifier: NCT01262144     History of Changes
Other Study ID Numbers: 421CTIL
First Posted: December 17, 2010    Key Record Dates
Last Update Posted: December 17, 2010
Last Verified: November 2010

Keywords provided by Rambam Health Care Campus:
Cervical Cancer

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female